Profitability and strong sales growth in 2008:
Net sales exceeded SEK 100 million
January - December
* Net sales increased by 35 % to SEK 100.4 million (74.6).
* The operating result increased to SEK 13.4 million (3.1).
* Profit before income tax increased to SEK 13.1 million (2.6).
* The net result per share amounted to SEK 1.05 (0.11).
* Cash and cash equivalents amounted to SEK 19.6 million (16.3) by
the end of the year.
* Continued strong sales on the European market and an increase in
North America.
* Establishment of own sales organization in the USA and
subsidiary in Japan.
* Launch of application for body fluids in Europe and North
America, with good initial sales results.
October - December
* Net sales for the fourth quarter increased by 97 % to SEK 38.3
million (19.4).
* The operating result amounted to SEK 7.1 million (3.0).
* Result per share amounted to SEK 0.80 (0.12).
Important events after the reporting period
* CellaVision was placed on NASDAQ OMX First North Premier on the
16th of February.
CellaVision in short
(MSEK) Q4 2008 Q4 2007 Helår 2008 Helår 2007
Net sales 38.3 19.4 100.4 74.6
Gross profit 21.1 14.1 63.5 45.3
Operating result 7.1 3.0 13.4 3.1
Profit before tax 7.0 2.8 13.1 2.6
Cash flow 8.3 0.1 3.3 -0.4
CEO's comment"It feels fantastic to report our highest sales and best result
so-far," says Yvonne Mårtensson, CEO of CellaVision. "Our
international expansion has proceeded according to plan and we have
succeeded in investing alongside increasing sales. We are now
operative in Japan and have established our own sales channel in the
US. As a result of Sysmex America's and our own sales activities the
North American sales proportion reached 45%. Europe is seeing a
continued positive sales growth and accounts for 54% of CellaVision's
sales.""2009 will be a year of challenges. Although medical technology
companies are generally regarded relatively stable, it would be
unreasonable to rule out the possibility of our industry being
negatively affected by the world economy. However, we believe that
our presence in a large number of countries combined with the
efficiency of our products is a winning concept also during rough
financial times. We are well equipped for future challenges."
For more information please contact:
Yvonne Mårtensson, CEO. Phone: 0708 33 77 82, e-mail:
yvonne.martensson@cellavision.se
Johan Wennerholm, CFO. Phone: 0708 33 81 68, e-mail:
johan.wennerholm@cellavision.se
Download the report by pressing the link below.
